Revisiting the use of sPLA 2 -sensitive liposomes in cancer therapy

Pourhassan, Houman; Clergeaud, Gael; Hansen, Anders Elias; Østrem, Ragnhild Garborg; Fliedner, Frederikke P.; Melander, Fredrik; Nielsen, Ole Lerberg; O’Sullivan, Ciara K.; Kjær, Andreas; Andresen, Thomas Lars

doi:10.1016/j.jconrel.2017.06.024

Cited by 41 publications

(26 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A comprehensive review on liposomal antitumor formulations is provided elsewhere [55,56]. The further directions in antitumor liposomal formulations progress are the development and improvement of stimuli-sensitive smart liposomes (thermo-, redox-, ultrasound-, enzyme-sensitive), magnetic liposomes, and liposomes for photodynamic therapy [57,58,59,60,61,62,63].…”

Section: Passive Targetingmentioning

confidence: 99%

Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency

Kutova

Guryev

Соколова

et al. 2019

Cancers

View full text Add to dashboard Cite

Malignant tumors are characterized by structural and molecular peculiarities providing a possibility to directionally deliver antitumor drugs with minimal impact on healthy tissues and reduced side effects. Newly formed blood vessels in malignant lesions exhibit chaotic growth, disordered structure, irregular shape and diameter, protrusions, and blind ends, resulting in immature vasculature; the newly formed lymphatic vessels also have aberrant structure. Structural features of the tumor vasculature determine relatively easy penetration of large molecules as well as nanometer-sized particles through a blood–tissue barrier and their accumulation in a tumor tissue. Also, malignant cells have altered molecular profile due to significant changes in tumor cell metabolism at every level from the genome to metabolome. Recently, the tumor interaction with cells of immune system becomes the focus of particular attention, that among others findings resulted in extensive study of cells with preferential tropism to tumor. In this review we summarize the information on the diversity of currently existing approaches to targeted drug delivery to tumor, including (i) passive targeting based on the specific features of tumor vasculature, (ii) active targeting which implies a specific binding of the antitumor agent with its molecular target, and (iii) cell-mediated tumor targeting.

show abstract

Section: Passive Targetingmentioning

confidence: 99%

Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency

Kutova

Guryev

Соколова

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…In conclusion, SPLA2 overexpression is observed in a significant subset of CAs correlating with aggressive biological behavior (progressive growth of malignant tumor). It is a crucial enzyme for cell response and metabolic homeostasis and also an interesting protein that cab potentially be a biomarker and therapeutic target (27,28). Although the current study included a relatively limited number of specimens for SPLA2 protein analysis, it seems that different grade and stage intensity levels may provide some information regarding the relationship between SPLA2 expression and cancer progression.…”

Section: Discussionmentioning

confidence: 97%

Secretory Phospholipase A2 Digital Expression Analysis in Colon Adenocarcinoma

Falidas

Kitsiouli

Spyropoulou

et al. 2022

In Vivo

View full text Add to dashboard Cite

Background/Aim: Phospholipases A2 represent a family of enzymes that regulate the metabolism of phospholipids by hydrolyzing them into fatty acids. Secretory phospholipase A2 (SPLA2) catalyzes the calcium-dependent 2-acyl groups hydrolysis to produce 3-sn-phosphoglycerides. This study aimed to investigate SPLA2 expression in colon adenocarcinoma (CA). Materials and Methods: Thirty (n=30) formalin-fixed, paraffin-embedded primary CA tissue sections were used and analyzed. Immunohistochemistry was performed using an anti-SPLA2 antibody. Digital image analysis was also implemented for evaluating objectively the corresponding protein expression levels. Results: Increased SPLA2 protein expression (high & moderate immunostaining levels) was observed in 23/30 (76.6%) cases, whereas 7/30 (23.4%) CA tissues demonstrated low protein levels. High expression levels were detected in 9/30 (30%) cases. SPLA2 overall expression was strongly associated with tumor diameter (p=0.004), whereas other statistically significant associations were not observed (stage: p=0.971, inflammatory infiltration: p=0.795; carcinoma location: p=0.340; differentiation grade: p=0.748; sex: p=0.369; ulceration: p=0.433). Conclusion: SPLA2 over-expression is observed in significant subsets of CAs correlating with advanced tumor growth progression (increased diameter). SPLA2 seems to influence endogenous cell responses by its crucial enzymatic activity and can potentially be a biomarker for monitoring CA patients.

show abstract

“…The LNP thus favors the release of siRNA with high efficiency by changing from negative to the positive charge. Pourhassan et al, 2017 [132], prepared oxaliplatin (L-OHP), a platinum drug in phospholipase A 2 (sPLA 2 )-sensitive liposomes for cancer therapy using negatively charged phospholipid desired to achieve enzyme sensitivity. The cell cytolysis is governed by the extent of lysolipids and the serum protein and the sensitivity of the formulation to the enzyme.…”

Section: Enzyme-responsive Lipidsmentioning

confidence: 99%

Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting

Rahim

Jan

Khan

et al. 2021

Cancers

113

View full text Add to dashboard Cite

The tumor-specific targeting of chemotherapeutic agents for specific necrosis of cancer cells without affecting the normal cells poses a great challenge for researchers and scientists. Though extensive research has been carried out to investigate chemotherapy-based targeted drug delivery, the identification of the most promising strategy capable of bypassing non-specific cytotoxicity is still a major concern. Recent advancements in the arena of onco-targeted therapies have enabled safe and effective tumor-specific localization through stimuli-responsive drug delivery systems. Owing to their promising characteristic features, stimuli-responsive drug delivery platforms have revolutionized the chemotherapy-based treatments with added benefits of enhanced bioavailability and selective cytotoxicity of cancer cells compared to the conventional modalities. The insensitivity of stimuli-responsive drug delivery platforms when exposed to normal cells prevents the release of cytotoxic drugs into the normal cells and therefore alleviates the off-target events associated with chemotherapy. Contrastingly, they showed amplified sensitivity and triggered release of chemotherapeutic payload when internalized into the tumor microenvironment causing maximum cytotoxic responses and the induction of cancer cell necrosis. This review focuses on the physical stimuli-responsive drug delivery systems and chemical stimuli-responsive drug delivery systems for triggered cancer chemotherapy through active and/or passive targeting. Moreover, the review also provided a brief insight into the molecular dynamic simulations associated with stimuli-based tumor targeting.

show abstract

Revisiting the use of sPLA 2 -sensitive liposomes in cancer therapy

Cited by 41 publications

References 45 publications

Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency

Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency

Secretory Phospholipase A2 Digital Expression Analysis in Colon Adenocarcinoma

Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting

Contact Info

Product

Resources

About